Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New study aims to unlock secrets of bee venom therapy failures

NCT ID NCT04259359

Knowledge-focused Sponsor: Medical University of Graz Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study is investigating why bee venom immunotherapy (VIT) doesn't work for some people. Researchers will test blood samples from 266 adults with bee venom allergy before they start treatment. They want to see if having a strong allergic response to a specific bee venom component, called Api m 10, predicts treatment failure. The goal is to improve future allergy shots so more people are protected from severe reactions.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
bee venom immunotherapy
What this could lead to
If successful, this could help doctors identify which patients are at risk of treatment failure and lead to better, more personalized bee venom allergy treatments.
What could go wrong
This is an observational study, not a treatment trial. It may not directly change care, and results might not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 266 people

The number the study aims to enrol. It can still change while the study runs.

Started

May 2019

Expected to finish

Mar 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patients who will be treated with bee venom immunotherapy

Ages

18 to 70 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Legally competent male and female subjects aged from 18 to 70 years with a history of a systemic anaphylactic sting reaction (≥ grade I according to the classification of Ring and Messmer) after bee stings, who will receive bee venom immunotherapy Exclusion Criteria: * Contraindications to VIT

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Bee venom allergy are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

venom allergy Venom Hypersensitivity

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Bee venom allergy

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    3 sites in 3 countries. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Department of Dermatology and Venerology, Medical University of Graz

    RECRUITING

    Graz, 8036, Austria

  • Elbe Klinikum Buxtehude

    RECRUITING

    Buxtehude, 21614, Germany

  • Hospital Universitario de Castellón

    RECRUITING

    Castellon, 12004, Spain

More trials for these conditions

Other studies related to the condition(s) this trial covers.